tiprankstipranks
The Fly

Alterity Therapeutics price target raised to $12 from $8 at Maxim

Alterity Therapeutics price target raised to $12 from $8 at Maxim

Maxim analyst Jason McCarthy raised the firm’s price target on Alterity Therapeutics (ATHE) to $12 from $8 and keeps a Buy rating on the shares after the company reported Phase 2 data for lead asset ATH434 in patients with early-stage multiple system atrophy. The data are “mixed but overall positive,” says the analyst, who adds that the relatively small trial should inform the design of a later-stage study.

Discover the Best Stocks and Maximize Your Portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1